JP2007510667A5 - - Google Patents

Download PDF

Info

Publication number
JP2007510667A5
JP2007510667A5 JP2006538522A JP2006538522A JP2007510667A5 JP 2007510667 A5 JP2007510667 A5 JP 2007510667A5 JP 2006538522 A JP2006538522 A JP 2006538522A JP 2006538522 A JP2006538522 A JP 2006538522A JP 2007510667 A5 JP2007510667 A5 JP 2007510667A5
Authority
JP
Japan
Prior art keywords
inhibitor
solvate
iii
salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510667A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/037027 external-priority patent/WO2005046678A1/en
Publication of JP2007510667A publication Critical patent/JP2007510667A/ja
Publication of JP2007510667A5 publication Critical patent/JP2007510667A5/ja
Pending legal-status Critical Current

Links

JP2006538522A 2003-11-07 2004-11-05 癌の治療法 Pending JP2007510667A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51821203P 2003-11-07 2003-11-07
PCT/US2004/037027 WO2005046678A1 (en) 2003-11-07 2004-11-05 Cancer treatment method

Publications (2)

Publication Number Publication Date
JP2007510667A JP2007510667A (ja) 2007-04-26
JP2007510667A5 true JP2007510667A5 (https=) 2007-12-27

Family

ID=34590233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538522A Pending JP2007510667A (ja) 2003-11-07 2004-11-05 癌の治療法

Country Status (4)

Country Link
US (1) US20070161665A1 (https=)
EP (1) EP1682123A1 (https=)
JP (1) JP2007510667A (https=)
WO (1) WO2005046678A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045134A1 (es) * 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
EA012181B1 (ru) 2004-10-18 2009-08-28 Амген, Инк. Соединения тиадиазола и их применение
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
PL2024372T3 (pl) * 2006-04-26 2010-11-30 Hoffmann La Roche Pochodna tieno[3,2-D]pirymidyny użyteczna jako inibitor PI3K
MX2008013578A (es) * 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
US20080051422A1 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-Aminoquinazoline derivatives and methods of use thereof
US20110053964A1 (en) * 2006-08-22 2011-03-03 Roger Tung 4-aminoquinazoline derivatives and methods of use thereof
EP2062597A4 (en) * 2006-09-15 2010-03-03 Univ Tokai PREVENTIVE OR CLEANING AGENT FOR ER-NEGATIVE AND HER2-NEGATIVE MAMMARY CARCINOMA AND INVESTIGATION METHOD THEREFOR
WO2008063853A2 (en) * 2006-11-21 2008-05-29 Smithkline Beecham (Cork) Limited Cancer treatment method
AU2008276512A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
WO2009137714A2 (en) 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
JP2011521214A (ja) * 2008-05-16 2011-07-21 セルゾーム アーゲー Ｐａｒｐ相互作用分子の同定およびｐａｒｐタンパク質の精製のための方法
US20100197915A1 (en) * 2008-08-06 2010-08-05 Leonid Metsger Lapatinib intermediates
SG177451A1 (en) * 2009-07-02 2012-02-28 Newgen Therapeutics Inc Phosphorus containing quinazoline compounds and methods of use
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
CZ2012712A3 (cs) 2012-10-17 2014-04-30 Zentiva, K.S. Nový způsob výroby klíčového intermediátu výroby lapatinibu
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
CN104109152A (zh) * 2013-04-19 2014-10-22 上海医药工业研究院 一种制备拉帕替尼的方法
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP2022512706A (ja) 2018-10-16 2022-02-07 エフ．ホフマン－ラ ロシュ アーゲー 眼科におけるＡｋｔ阻害剤の使用
KR20250144394A (ko) * 2023-01-20 2025-10-10 덤바이온트, 인코포레이티드 피부 질환, 병태, 및 장애의 예방, 치료, 및 개선을 위한 조성물 및 제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
JP2001247477A (ja) * 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd 抗腫瘍剤
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs

Similar Documents

Publication Publication Date Title
JP2007510667A5 (https=)
LTPA2017011I1 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
PT1506781E (pt) Composicao para tratamento vaginal
EP2210092A4 (en) SEMAPHORINE COMPREHENSIVE COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO ANGIOGENESIS AND SELECTION PROCEDURES THEREFOR
JP2004504382A5 (https=)
JP2009502793A5 (https=)
JP2009502743A5 (https=)
EP1311262A4 (en) CANCER THERAPY THROUGH COMBINATION THERAPY
JP2006515626A5 (https=)
IL182010A0 (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
EE05394B1 (et) Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
JP2007537301A5 (https=)
SI1701944T1 (sl) Amino substituirani aril piramidini in povezane spojine uporabne pri zdravljenju vnetnih bolezni
JP2006514116A5 (https=)
EP2207892A4 (en) METHOD FOR SELECTION OF ACTIVE AGENTS FOR CANCER TREATMENT
JP2008513510A5 (https=)
EP1970063A4 (en) THERAPEUTIC AGENT AGAINST DIABETES
FR2864552B1 (fr) Traitement de surface par hydroxysulfate
JP2008524329A5 (https=)
WO2008028963A3 (en) Calreticulin for its use as a medication for the treatment of cancer in a mammal
NO20070892L (no) Sammensetninger av N-glykolylneuraminsyre og anvendelse derav ved behandling av forkjølelse.
JP2008517059A5 (https=)
SI1545710T1 (sl) Uporaba N-(3-metoksi-5-metilpirazin-2-il)-2-(4-(1,3,4-oksadiazol-2-il)fenil) piridin-3-sulfonamida v zdravljenju raka
BRPI0821116A2 (pt) Composto, composição farmacêutica que o contem, uso deste e método para tratar qualquer mamífero afetado por câncer
ZA200704104B (en) A combination of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer